Aptamer News and Research

RSS

Wearable microneedle patch tracks antibiotic levels in real time

A wearable patch with microneedles coated in DNA molecules tracks levels of antibiotics in the body in real time.

21 Sep 2026

Innovative device improves real-time monitoring of donated lungs

More than three-quarters of donated lungs offered for transplantation are not used, according to the UK's National Institute for Health and Care Excellence, contributing to a chronic shortage of organs for patients with end-stage lung disease.

10 Sep 2026

New EV-SELEX strategy accelerates drug discovery for wide range of GPCRs

G protein-coupled receptors (GPCRs) are the most abundantly expressed proteins in the human body, which regulate diverse physiological processes ranging from pain perception to hormone signaling.

7 Jul 2026

Why clinical proteomics faces a mass spectrometry vs. high-throughput profiling dilemma

This Clinical Chemistry and Laboratory Medicine review examines a central challenge in precision medicine: whether medical laboratories should prioritize metrologically sound, proteoform-resolving protein quantification by mass spectrometry or adopt scalable, affinity-based proteome profiling platforms built for high-throughput discovery and machine learning. It concludes that while emerging proteomics technologies expand diagnostic possibilities, careful validation, standardization, and quality assurance will be essential, with a hybrid path likely offering the most practical way forward.

19 Apr 2026

Aptamer Group launches targeted radiopharmaceutical program

Aptamer Group plc, the developer of next‑generation synthetic binders for the life sciences industry, today announced the launch of a new targeted radiopharmaceutical program in collaboration with Radiopharmium Ltd, a UK-based specialist consultancy in radiopharmaceutical development.

From Aptamer Group 18 Mar 2026

Researchers develop DNA aptamer to detect Alzheimer's biomarkers

With aging populations on the rise, the need for better tools to diagnose and monitor Alzheimer's disease (AD), the most common cause of dementia, has never been more urgent.

10 Mar 2026

Aptamer-based wearables revolutionize continuous health tracking

Continuous monitoring of biomarkers is essential for early disease detection, treatment evaluation, and personalized health management, yet most clinical tests rely on invasive, single-point blood sampling. Recent advances in aptamer-based wearable electrochemical sensors offer a promising alternative by enabling real-time, continuous tracking of physiological signals directly in or on the body.

30 Jan 2026

HonorHealth patient first in Arizona to receive new investigational treatment for ischemic stroke

A stroke patient at HonorHealth Research Institute is the first in Arizona to receive a new investigational treatment that targets platelets - rather than traditional clotting proteins - to help reopen blocked blood vessels in the brain.

20 Jan 2026

Aptamer-based biosensors could transform viral detection

Rapid and reliable virus detection is one of the most critical tools for controlling outbreaks, from seasonal influenza to global pandemics like COVID-19.

9 Jan 2026

Aptamer Group and Alphazyme execute licensing agreement for synthetic aptamer-based enzyme modulation in hot-start PCR

Aptamer Group plc, a developer of synthetic oligonucleotide-based binding reagents for life sciences applications, and Alphazyme LLC (Alphazyme), a Maravai LifeSciences company specializing in enzymes for molecular biology, have executed a licensing agreement for a proprietary Optimer® binder developed for hot-start polymerase chain reaction (PCR) applications.

From Aptamer Group 24 Dec 2025

Top-five pharmaceutical company expands partnership with Aptamer for multi-target Optimer® development program

Aptamer Group plc, the developer of next-generation synthetic binders for the life sciences industry, today announced a new contract valued at up to £617,000 with a top-five pharmaceutical company.

4 Nov 2025

A new technique to tag senescent cells

When it comes to treating disease, one promising avenue is addressing the presence of senescent cells. These cells - also known as "zombie cells" - stop dividing but don't die off as cells typically do.

27 Oct 2025

Montreal chemists develop fast DNA-based sensor for drug monitoring

Chemists at Université de Montréal have developed "signaling cascades" made with DNA molecules to report and quantify the concentration of various molecules in a drop of blood, all within 5 minutes.

16 Oct 2025

Aptamer expands into targeted radiopharmaceuticals with major top 3 pharma contract

Aptamer Group plc, the developer of next-generation synthetic binders for the life sciences industry, has announced a significant development contract with a top 3 global pharmaceutical company to engineer Optimer® binders as targeted radiopharmaceuticals for potential therapeutic applications.

8 Oct 2025

Aptamer signs therapeutic development agreement with Invizius

Aptamer Group plc, the developer of next-generation synthetic binders for the life sciences industry, is pleased to announce that it has signed a new therapeutic development agreement with Invizius, a clinical-stage biotechnology company focused on second-generation complement system therapies for inflammatory, fibrotic, and autoimmune diseases.

From Aptamer Group 2 Sep 2025

Aptamer Group introduces novel biomarker discovery service

Aptamer Group plc, the leading developer of next-generation synthetic binders delivering innovation to the life science industry, today announced the launch of its biomarker discovery service, offering researchers in pharmaceutical, biotechnology, and diagnostic development an innovative approach to identify and validate new disease markers.

28 Aug 2025

2025 Chikungunya outbreak: A global health challenge

Chikungunya virus (CHIKV) is a mosquito-borne alphavirus causing fever, severe joint pain, rash, and muscle aches, mainly transmitted by Aedes mosquitoes. As of 2025,

From Sino Biological Inc. 18 Aug 2025

New technique creates multimeric aptamers for precision virus targeting

We have all heard of antibodies – proteins produced by our bodies to bind to viruses or bacteria, marking them for elimination by the immune system.

6 Jun 2025

Optimer licensing agreements and repeat custom

Aptamer Group plc, the leading developer of next-generation synthetic binders delivering innovation to the life science industry, has announced two new development contracts for Optimer binders and the agreement of licensing heads of terms with a global provider of specialty enzymes for developed enzyme-modulating Optimers.

From Aptamer Group 16 May 2025

Aptamer announces new data at ASGCT

Aptamer Group plc, the leading developer of next-generation synthetic binders delivering innovation to the life science industry, presented new data on its Optimer therapeutic delivery vehicle for liver fibrosis at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in New Orleans, LA (13-17 May 2025).

From Aptamer Group 16 May 2025